Target intelligence / Profile preview

Polyclonal mixture of pathogenic antigens, toxins, and host immune components

Molecular classification
Other
01

Overview

The 'Polyclonal mixture of pathogenic antigens, toxins, and host immune components' refers to the broad array of inflammatory and infectious mediators present in the systemic circulation during severe illness, such as sepsis or systemic inflammatory response syndrome (SIRS) (Nierhaus et al., 2018, Critical Care). This heterogeneous target includes pathogen-associated molecular patterns (PAMPs) like bacterial endotoxins, damage-associated molecular patterns (DAMPs), and a variety of host-derived cytokines including Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-alpha) (Monard et al., 2023, J. Clin. Med.). Because these components drive the 'cytokine storm' and subsequent multi-organ failure, they are the focus of broad-spectrum therapeutic interventions (CytoSorbents Corp, 2023). Therapeutic approaches include extracorporeal blood purification devices like CytoSorb, which utilize polymer beads to adsorb these substances, and intravenous immunoglobulin (IVIG) preparations that provide polyclonal antibodies to neutralize toxins and antigens (Perez et al., 2017, J. Allergy Clin. Immunol.). The primary clinical objective in targeting this mixture is to reduce the overwhelming inflammatory burden and restore immunological balance in critically ill patients.

Other names
Inflammatory mediatorsSeptic mediatorsCytokine and toxin poolPathogen-associated molecular patterns (PAMPs)Damage-associated molecular patterns (DAMPs)Humoral inflammatory components
02

Mechanism of action

Extracorporeal adsorption of inflammatory mediators and toxins; Neutralization of antigens and toxins via polyclonal antibody binding.

03

Biological functions

Immune responseInflammationPathogenesisSignal transduction
04

Disease associations

SepsisSeptic shockSystemic Inflammatory Response Syndrome (SIRS)Cytokine stormMulti-organ failureInfection
05

Safety considerations

Non-specific removal of therapeutic drugs (e.g., antibiotics)ThrombocytopeniaHypocalcemia (with citrate anticoagulation)Potential removal of beneficial anti-inflammatory mediatorsHemolysis
06

Interacting drugs

CytoSorb

3 more in the full profile.

07

Biomarkers

Interleukin-6 (IL-6)C-reactive protein (CRP)Procalcitonin (PCT)Tumor necrosis factor-alpha (TNF-alpha)Lactate

Beyond the preview

Go deeper on Polyclonal mixture of pathogenic antigens, toxins, and host immune components.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polyclonal mixture of pathogenic antigens, toxins, and host immune components.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call